U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07292909) titled 'Effect of Empagliflozin on Inflammation' on Dec. 06.
Brief Summary: Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure. The exact mechanism of this effect is currently not clearly understood.
He hypothesize that empagliflozin has other properties than glucose lowering, that can explain its efficacy. One of these properties, is an anti-inflammatory effect.
To document this, we are using a model of inflammation following percutaneous coronary scenting. We know that patients who get a stent wil...